SCHEMBL3304813

SCHEMBL3304813

NC1CCCC2C1=CC=C1C=CCCC12

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31097915 0.88
SCHEMBL11189349 0.80
SCHEMBL28479248 0.76
SCHEMBL1572254 0.74
SCHEMBL15422795 0.73 NOS1 (0.31)
Hydrazine SCHEMBL1572402 0.70 KDM1A (0.30)
SCHEMBL11702792 0.69
SCHEMBL821855 0.69
SCHEMBL29493533 0.68
SCHEMBL9430980 0.67 MAPT (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1175383-B1 GLUCOCORTICOID RECEPTOR MODULATORS PFIZER PROD INC (US) 2018-03-14 EP disclosed
EP-1521733-B1 MODULATORS OF THE GLUCOCORTICOID RECEPTOR PFIZER PROD INC (US) 2014-08-20 EP disclosed
US-7713989-B2 Glucocorticoid receptor modulators DOW ROBERT L 2010-05-11 US disclosed
US-7553877-B2 Use of 2-hydroxy-1,2,3,4,4a,9,10,10a-octahydrophenanthrene compounds glucocorticoid receptor agonists to treat certain inflammatory conditions such as arthritis, asthma PFIZER, INC. (US) 2009-06-30 US disclosed
US-20070129410-A1 Octahydrophenanthrene hydrazinde derivatives useful as glucocorticoid receptor modulators PFIZER INC. 2007-06-07 US disclosed
US-20070117805-A1 Glucocorticoid receptor modulators PFIZER INC. 2007-05-24 US disclosed
US-7166593-B2 Glucocorticoid receptor modulators PFIZER, INC. (US) 2007-01-23 US disclosed
US-7138406-B2 Antiinflammatory agents; antiallergens; vision defects; anticancer agents; gastrointestinal disorders PFIZER, INC. (US) 2006-11-21 US disclosed
US-20060247264-A1 Use of 2-hydroxy-1,2,3,4,4a,9,10,10a-octahydrophenanthrene compounds glucocorticoid receptor agonists to treat certain inflammatory conditions such as arthritis, asthma PFIZER INC 2006-11-02 US disclosed
EP-1685110-A1 OCTAHYDROPHENANTHRENE HYDRAZIDE DERIVATIVES USEFUL AS GLUCOCORTICOID RECEPTOR MODULATORS Pfizer Products Inc. (US) 2006-08-02 EP disclosed
US-20020107235-A1 Glucocorticoid receptor modulators LIU KEVIN K (US) 2002-08-08 US disclosed
EP-1201649-A1 Glucocorticoid receptor modulators Pfizer Products Inc. (US) 2002-05-02 EP disclosed
EP-1201660-A1 Glucocorticoid receptor modulators Pfizer Products Inc. (US) 2002-05-02 EP disclosed
US-6380223-B1 FOR THERAPY OF DISEASES, SUCH AS OBESITY, DIABETES, INFLAMMATION PFIZER INC. 2002-04-30 US disclosed
EP-1175383-A1 GLUCOCORTICOID RECEPTOR MODULATORS Pfizer Products Inc. (US) 2002-01-30 EP disclosed
WO-2000066522-A1 GLUCOCORTICOID RECEPTOR MODULATORS PFIZER PRODUCTS INC. (US) 2000-11-09 WO disclosed
US-5276053-A Dibenzothiopyranylamines WARNER-LAMBERT COMPANY (US) 1994-01-04 US disclosed
US-5180736-A Treatment and prevention of brain disorders WARNER-LAMBERT COMPANY (US) 1993-01-19 US disclosed
US-5071853-A Amine-substituted hexahydroindeno(2,1-b)pyrroles, -indeno(2,1-c)pyridines or -indeno(2,1-d)azepines; cerebral ischemia or infarction WARNER-LAMBERT COMPANY 1991-12-10 US disclosed
EP-0388977-A2 Polycyclic amines useful as cerebrovascular agents WARNER-LAMBERT COMPANY (US) 1990-09-26 EP disclosed